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Abstract
Purpose: The impact of computed tomography (CT)-guided, percutaneous radiofrequency ablation and interstitial 
laser ablation (ILA) on the management of patients with osteoid osteoma was studied. This was carried out by assess-
ing immediate and long-term clinical outcomes, the complication rate, and repeat therapy effectiveness in recurrent 
patients who have already experienced percutaneous ablation.
Material and methods: Consecutive patients with osteoid osteoma were assessed before the interventional treatment in 
a single centre from 2010 to 2015. Patient demographics, complications, and recurrence were recorded. The pain was 
evaluated with Visual Analogue Scale (VAS). Percutaneous procedures were performed by means of radiofrequency 
thermoablation or ILA. Epidural or regional anaesthesia in the CT suite was applied in all procedures. Success, 
whether primary or secondary, was measured as complete pain relief without evidence of recurrence after the first 
or second procedure, respectively. Osteoid osteoma characteristics, procedure overview, and technical success were 
looked for in pre-procedural and procedural scans.
Results: Eighty-three per cent of osteoid osteomas were located in lower extremities, 56% of tumours were intracor-
tical, and 83% of osteoid osteomas were extra-articular. The mean pre-procedure VAS score was 8.5 ± 0.8, while the 
overall primary success rate of radiofrequency thermoablation and ILA was 87.5%. No major complications were 
noted. The mean follow-up period for patients in was 7.5 years (5.0-10.2 years).
Conclusions: Percutaneous, CT-guided thermoablation proved to be effective and should become the method of choice 
in osteoid osteoma treatment because of its minimal invasiveness. Our results show that there is no risk of very late 
recurrence after achieving primary and secondary treatment success.
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Introduction 
In 1930 Bergstrand first described osteoid osteoma (OO) 
as a benign tumour. Jaffe followed this concept in 1935 
[1,2]. The tumour accounts for ~10 to 12% of all benign 
bone tumours, most frequently occurring in the second 
and third decades of life, with a male preponderance [3-5]. 
The tumour is composed of vascularised callus and primi-
tive (woven) bone (called a nidus) surrounded by a zone 
of reactive sclerosis, where compact bone of different de-
grees of maturity is observed [6]. The tumour is found 
mainly in long bones; over 50% of cases are located in the 
femur or the tibia [7,8]. The lesion is usually located in the 
proximal part of the femur (diaphysis) and rarely in the 
epiphysis. Based on its location in an axial cross-section, 
OO is described as subperiosteal, intracortical, endos-
teal, or medullary, and depending on its relation to the 
articular capsule attachment, as extra- or intra-articular 
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[6,9]. The leading clinical manifestation of OO is pain [7]. 
The pain typically intensifies at night and subsides quick-
ly after the administration of salicylates (within about 
30 minutes) [10]. Prostaglandins were found to have taken 
active part in the production of pain in patients with OO. 
The elevation of the prostaglandin level from 100 to 1000 
times the normal level was found to take place within the 
nidus of the lesion [11]. Besides the production of pros-
taglandins in the lesion, the pain is related to the pres-
ence of unmyelinated nerve fibres within it [12,13]. The 
pain may be accompanied by local oedema and tender-
ness and, in children, by more dramatic manifestations, 
such as stunted growth and neurological manifestations. 
With intra-articular tumours, the presentation may be 
misleading and suggest a primary articular pathology. 
The manifestations include tenderness, mobility limita-
tion, contracture, and joint effusion. The lesion causes 
synovial hypertrophy and articular cartilage damage, 
which may lead to early onset of degenerative changes [7]. 
Laboratory workup is usually negative. Effective surgical 
treatment requires the complete removal of the nidus [14]. 
Depending on the lesion size and location, the extent of 
bone resection varies from minimal to extensive. If a sub-
stantial amount of cortical bone is removed, there is risk 
of fracture at weight bearing sites. In such cases internal 
fixation and bone grafting may be prove necessary. Due 
to the implementation of improved methods, taking ad-
vantage of computed tomography, the precise localisation 
of an OO has been made possible in the treatment of this 
lesion with more limited operations, especially percutane-
ous ablation [4,15]. Computed tomography (CT)-guided 
percutaneous radiofrequency thermoablation (RFA) and 
interstitial laser ablation (ILA) are effective techniques 
that have been universally acknowledged as a minimally 
invasive, safe, and cost-effective cure for OO [16-19].
However, the long-term efficacy of ablation in the 
treatment of OO has been examined more closely. What 
was found was that an important parameter concerning 
delayed OO recurrences was reported up to 10 years af-
ter surgical resection and RFA with CT-guidance [20-23]. 
The impact of CT-guided, percutaneous RFA or ILA on 
the management of patients was closely examined by 
evaluating the exclusion rate, immediate and long-term 
clinical outcomes with a minimum of a 5-year follow-up, 
the rate of complications, and the effectiveness of repeat 
therapy in recurrent patients having already experienced 
percutaneous ablation, despite this group being small. 
Material and methods
Demographic data
Between 2010 and 2015, 20 patients underwent qualifica-
tion for percutaneous OO thermoablation at a single cen-
tre. All procedures performed in studies involving human 
participants were in accordance with the ethical standards 
of the institutional review board. Informed consent was 
obtained from all individual participants included in 
the study. The age of patients ranged from 5 to 34 years 
old (mean: 19 years old). Our population consisted of 
11 males and 9 females, giving a sex ratio of 1.2 : 1. 
Analysis and management of osteoid osteoma
All patients had typical histories, and we confirmed the 
presence of a nidus using CT examinations, also in order 
to obtain detailed information. CTs were performed on 
a 64-detector CT scanner (Aquillion 64; Toshiba Medi-
cal Systems Corporation, Otawara, Japan). The images 
were reconstructed with a section thickness of 0.5 mm, 
using a bone reconstruction kernel. Images were assessed 
on a dedicated workstation (IntelliSpace Portal, Philips 
Healthcare, Eindhoven, Nederland) at a single centre. 
Baseline data included OO location and imaging fea-
tures. The nidus maximal diameter was calculated on axial 
planes, and the maximal area of the nidus was calculated 
on reformatted planes using multiplanar CT images for 
the benefit of manual measurements. For the software-
aided CT measurements of the nidus volume, images 
were evaluated at a workstation (IntelliSpace Portal), and 
volume-rendered images were used in CT volume calcula-
tions. By using the auto counter tool, no manual adjust-
ments were performed, so as to obtain optimal automated 
nidal volume calculations. Lesions were classified on the 
basis of location: subperiosteal, intracortical, endosteal, 
or medullary in accordance with the criteria of Kayser 
et al [9]. Based on their relation to the articular capsule at-
tachment, OO were divided into extra- or intra-articular. 
Nidus calcifications were also assessed. Perinidal cortical 
or intramedullary reactive sclerosis was measured. In or-
der to access each OO and type of ablation, procedural 
notes were reviewed to determine the number of osse-
ous channels used. RFA and ILA procedures were defined 
to be radiologically successful when an RFA electrode or 
ILA needle were successfully placed centrally in the nidus. 
Then the distance between the nidus and skin at the place 
of needle entry was measured.
Patient selection
Whether to treat by RFA or ILA, a multidisciplinary 
musculoskeletal oncology consultative meeting was 
held. The clinical diagnosis of OO was suspected when 
predominantly nocturnal pain, not related to physical 
activity, was typically relieved by NSAIDs. If a patient 
suffered from clinically significant pain, evaluated on 
a 0-10 Visual Analogue Scale (VAS) over 24 h prior, this 
was considered an eligibility criterion. Pain was con-
sidered clinically significant if it reached a score of 6 or 
more on VAS [24]. This algic threshold was considered 
an inclusion criterion regardless of clinically significant 
functional limitations.
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In addition to using good medical judgment when 
seeking potential candidates for this therapy, the follow-
ing exclusion criteria were considered:
•	 target lesion < 1 cm away from the skin, neurovascular 




•	 contraindication to deep sedation/general anaesthesia,
•	 lack of written informed consent.
When not all clinical or radiological criteria were met, 
a biopsy was performed before or during the RFA or ILA 
procedure. Neither the absence of histological confirma-
tion of the diagnosis nor prior treatment having been 
performed were considered to be an exclusion criterion.
Pre-procedure 
Before the percutaneous thermoablation procedure was 
carried out it was carefully explained to all patients, and 
alternative treatments, such as open surgery or pharma-
ceutical treatment, were presented. Before ablation, all 
patients had to give their informed consent (in the case 
of minors, from parents). Prior to treatment, all patients 
were evaluated by an experienced orthopaedic surgeon 
(HK). The evaluation constituted a full physical examina-
tion including an assessment of the pain level.
Procedure
CT guidance was used in the performance of RFA and 
laser ablations (Toshiba Aquilion 64, Toshiba Medical Sys-
tems Corporation, Japan). The procedures took place on 
an in-patient basis and were carried out by an interven-
tional radiologist and orthopaedic surgeon in a CT room. 
A CT scanner was then used to localise the tumour nidus, 
guide the needle placement within the tumour nidus, and 
depict carbonisation. The use of 0.5-mm-thick contigu-
ous sections through the region of interest helped local-
ise the tumour at CT. After precisely locating the tumour 
by CT scanning, the skin entry point and approach were 
determined. The dimensions of the nidus were measured 
at CT, which enabled the measurement of the amount of 
energy required to coagulate the tumour. Upon applying 
bone drilling, CT-fluoroscopy guidance was used to depict 
needle progression (Figure 1).
Because the pain during the penetration of the needle 
into the nidus is excruciating, patients were given spinal 
anaesthesia in the case lower extremity lesions. Those with 
a lesion in an upper limb were given a regional nerve block. 
Following a small skin incision, each OO nidus was accessed 
with a 14-gauge Bonopty (AprioMed AB, Uppsala, Sweden) 
coaxial bone biopsy system (Figure 2). At this moment tis-
sue sampling was attempted for a few lesions. Before treat-
ment, a typical broad-spectrum antibiotic was applied.
Figure 1. Multislice computed tomography (CT) fluoroscopy allows the guidance and placement of the needle to be monitored in 3D. Acquisition of 3 con-
tiguous CT slices of varying thickness permits a volumetric approach with precise management of the patient’s z-axis and accurate depiction of the needle 
progression when bone drilling
Figure 2. A 14-gauge Bonopty (AprioMed AB, Uppsala, Sweden) coaxial 
bone biopsy system
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Computed tomography-guided percutaneous bipolar 
radiofrequency ablation procedure
The internal drill or stylet of the Bonopty Penetration 
Set was exchanged with the radiofrequency electrode. To 
ensure that there was no contact between the cannula 
and electrode, the cannula was retracted over the elec-
trode. An 18-gauge bipolar electrode (Celon ProSurge 
micro, Olympus, Germany) was used for RF ablation 
(Figure 3). We used non-cooled electrodes with 9 mm 
active tips in lesions less than 1 cm and 15 mm in lesions 
more than 1 cm in maximum diameter. With the elec-
trode connected to the RF generator, power was set at 
3 W and energy application increased to 5 W max. Once 
a resistance of 900 Ω was reached, the procedure was 
terminated. Because we used a bipolar RF system, there 
was no requirement for the placement of grounding 
pads.
Laser ablation procedure
To perform ILA, a portable, continuous-wave, semicon-
ductor diode laser (model CTL Doris Plus, CTL, Warsaw, 
Poland) with an 810-nm wavelength was used. Laser en-
ergy was delivered with a flexible, single-use, bare-tipped, 
400-μm fibre with polymer cladding. The fibre was not 
radiopaque; therefore, before insertion, the fibre was 
inserted into the 18-gauge spinal needle, and its length 
adapted and marked. Upon location confirmation of the 
tip of the 18-gauge spinal needle within the centre of the 
nidus with CT, the 400-μm fibre was placed in the needle. 
It was then withdrawn by 5 mm to expose the tip of the 
bare fibre within the tumour. The diode laser was set in 
the continuous-wave mode delivering 2 W of power for 
a calculated number of seconds to achieve total energy. 
The amount of energy delivered was adjusted according to 
the formula (NS × 100 J) + 200 J, where NS is nidus size in 
millimetres. A maximum energy of 1200 J was most com-
monly applied to avoid damage to surrounding structures 
and to coagulate the nidus. 
Discharge
All patients were hospitalised for 1-2 nights after RFA or 
ILA, depending on the severity of the post-procedural 
pain. Acetaminophen was recommended for routine pain 
control, and patients were prescribed acetaminophen with 
codeine for PRN pain control during the first 24 h of the 
post-procedure period. Before being discharged, each pa-
tient was assessed and examined for bleeding, swelling, 
skin burn, neurovascular complications, and other pro-
cedure-related problems, to assess the technical success 
rate. All patients were instructed to avoid strenuous high 
impact activity for 6 weeks after the procedure.
Clinical success rate
OO-related pain was defined as pain of similar location 
and quality compared to originally reported symptoms. 
VAS was used to assess a patient’s pain levels [24]. Pri-
mary clinical success was measured as OO-related pain 
1 month after RFA or ILA without additional intervention 
such as repeat RFA or repeat ILA. Long-term treatment 
success was defined as a lack of medically documented 
OO recurrence with no OO-related pain at the time of 
follow-up. 
Follow-up
After the first month of the procedure, a full physical ex-
amination was carried out. Data on direct and indirect 
changes in pain levels and function were also assessed. 
Subsequently patients were evaluated every 3 months 
during the first year and annually thereafter. All patients 
were informed that OO is a bone tumour, and the follow-
up was necessary to confirm full recovery. For patients 
under 18 years of age, the patient’s legal guardian was in-
terviewed. The patients were informed that in the case of 
any pain recurrence, they should immediately contact the 
department.
Results
Rejection from percutaneous thermoablation
Four patients (4/20) failed to meet the inclusion criteria 
and were excluded from thermoablation. Contraindica-
tions to percutaneous RFA or ILA are shown in Table 1.
Figure 3. A) RF ablation needle (Celon ProSurge, Olympus), with the active 
tip (B) 
Table 1. Excluded procedures
Candidate Nidus location Contraindications 
to thermoablation
I Pedicle of vertebral arch Less than 1 cm 
to neural structure
II The head of the fibula Less than 1 cm 
to neural structure
III Talus Too close to the skin
IV Femur Lack of consent
 Osteoid osteoma percutaneous ablation
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Clinical success and long-term outcome
Sixteen patients met the criteria for inclusion in the RFA 
or ILA. Patients’ characteristics and data of the procedures 
are summarised in detail in Table 2.
The mean pre-procedure VAS score was 8.5 ± 0.8. In 
14 patients, the VAS score dropped to 0 by the end of first 
month post procedure. Two patients experienced recur-
rent pain (VAS = 7-8), and we confirmed that 2 patients 
had recurrences – both lesions were in the proximal fe-
mur. Patient #8 was retreated with RFA ablation, Patient 
#10 was converted to ILA – both patients remained symp-
tom-free and were considered as cured based on their 
patient records. Two patients (Patient #3 and Patient #7) 
were referred to us with recurrence of pain after previous 
surgical resection of the nidus in another hospital. There 
was complete resolution of pain after the first percutane-
ous treatment in them. One patient developed a minor 
complication. Long-term follow-up was obtained for 
16 patients. The follow-up period was for a maximum of 
10.2 years (range 5.0-10.2 years; mean 7.5 years).
Histological findings 
The clinical and radiological criteria were met in the 
majority of cases, and a biopsy was not performed. Tissue 
sampling was attempted for a few lesions during the RFA 
or ILA procedures, and histological confirmation of OO 
was determined. 
Analysis and management of osteoid osteoma
All the patients in our study had a standard CT scan. Le-
sion characteristics are shown in Table 3.
In our study, 14 of the OO (83%) were located in lower 
extremities, whereas 12% (n = 2) of lesions were in upper 
limbs. The lesions were located in the femur (n = 8), tibia 
(n = 5), talus (n = 2), calcaneus (n = 1), ulna (n = 1), and 
metacarpal bone (n = 1). CT demonstrated in most of the 
cases a lytic nidus with surrounding reactive sclerosis and 
adjacent cortical thickening. The imaging criteria indicat-
ed intracortical OO in 56% of patients (9/16), subperios-
teal in 31% (5/16), and endosteal in 13% (2/16). Eighty-
three per cent of tumours (14/16) were extra-articular. 
The procedure was technically successful in all the cases. 
All tumours were accessed via a single osseous channel, 
except one lesion for which 2 channels were required. 
Discussion
Excluded procedures
From 2010 to 2015, we evaluated 20 patients affected by 
OO. In the study, ablation to tumour nidi occurring at 








Length of needle tract from 
entry point to the nidus 
(mm)
Perinidal reactive sclerosis 
and cortical thickness  
at entry point (mm)
Duration of clinical 
follow-up (years)
1/12/F Laser ablation 1 66 3.0 5.3
2/16/M Laser ablation 1 22 6.7 5.0
3/32/M Laser ablation 1 28 1.1 5.7
4/26/M Laser ablation 1 29 7.0 6.1
5/14/F Celon ProSurge 1 21 2.0 7.1
6/5/M Celon ProSurge 1 43 9.0 7.5
7/21/M Celon ProSurge 1 24 1.2 7.2
8/12/F Celon ProSurge 1 62 4.5 8.5
9/34/F Celon ProSurge 1 14 1.4 7.7
10/21/M Celon ProSurge 2 88 7.2 8.1
11/28/F Celon ProSurge 1 45 3.2 7.7
12/7/M Celon ProSurge 1 14 3.8 8.1
13/18/F Celon ProSurge 1 63 5.6 8.4
14/17/M Celon ProSurge 1 38 4.2 8.0
15/18/M Celon ProSurge 1 11 5.8 9.2
16/22/F Celon ProSurge 1 47 1.0 10.2
8’/13/F Celon ProSurge 1 62 2.3 7.7
10’/22/M Laser ablation 1 88 12.0 7.3
Mean (min; max) 42.5 (11.0; 88.0) 4.53 (1.0; 12.0) 7.5 (5.0; 10.2)
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least 10 mm from vital tissues (e.g. neurological, skin) had 
to be limited to avoid tissue damage. Of 20, we excluded 
4 patients from percutaneous ablation because the treat-
ment was declined according to our exclusion criteria. In 
1 patient vertebral lesion was in contact with the nerve 
root where it passes through the L2-L3 intervertebral fo-
ramen (Figure 4). One patient had a lesion of the head of 
the fibula located 9 mm from the common fibular nerve. 
In one patient lesion was in contact with the skin. One 
patient failed to give informed consent.
Due to the positioning of OO located in the pedicle 
or close to the nerve roots, Rosenthal et al. believed that 
most patients are not good candidates for RF ablation be-
cause of the risk to nerves [17]. While Gangi et al. and 
Hoffmann et al. found the therapy save, especially when 
used with an infusion of saline technique via an additional 
needle to produce an effective insulator [16,25]. Another 
technique to avoid heat-related skin necrosis, especially 
in patients with OO in the radius or tibia, is the sterile 




























1/12/F Femur Subperiosteal Extra-articular 8 110 547 7
2/16/M Calcaneus Endosteal Extra-articular 4.4 20 54 1.5
3/32/M Tibia Subperiosteal Extra-articular 4 40 64 3
4/26/M Ulna Endosteal Extra-articular 4 22 67 0.5
5/14/F Neck of talus Subperiosteal Extra-articular 9 78 374 3
6/5/M Trochanter minor 
of the femur
Intracortical Extra-articular 4.5 14 37 0.5
7/21/M Tibia Subperiosteal Extra-articular 5.4 17 114 1.4
8/12/F Collum femoris Intracortical Intra-articular 5.7 46 176 4
9/34/F Metacarpal III Intracortical Extra-articular 2 3 6 0
10/21/M Trochanter minor 
of the femur
Intracortical Extra-articular 12 178 1290 0
11/28/F Femur Intracortical Extra-articular 3.7 12 39 2
12/7/M Tibia Intracortical Extra-articular 4.7 21 66 5
13/18/F Trochanter minor 
of the femur
Intracortical Extra-articular 6 27 77 3
14/17/M Tibia Intracortical Extra-articular 5.6 44 216 2
15/18/M Tibia Intracortical Extra-articular 3.4 13 58 0
16/22/F Collum femoris Subperiosteal Intra-articular 8 54 274 4
8’/13/F* Collum femoris Intracortical Intra-articular 5.7 34 170 4
10’/22/M* Trochanter minor 
of the femur
Intracortical Extra-articular 8.4 60 476 0
Mean (min; max) 5.65 (2; 12) 44 (3; 178) 217 (6; 1290) 2.3 (0; 7)
*Patients #8’ and #10’ with OO recurrence with repeated assessment before second thermoablation
Figure 4. Sagittal T2-weighted spin-echo magnetic resonance image with 
fat suppression shows nidus with a central area of low signal intensity 
(arrow) in contact with the nerve root where it passes through the L2-L3 
intervertebral foramen. Note bone marrow oedema (arrowheads) in arti-
cular processes 
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draping of commercially available cool packs. Cool packs 
could be positioned around the needle shaft at the entry 
point to secure the sufficient cooling of overlying skin and 
soft tissues. Patient selection is a critical step to the suc-
cessful execution of OO percutaneous treatment. 
Short-term outcome 
Lesions in all other anatomical sites were included 
(16/20), percutaneous ablation of the OO had been car-
ried out at our institution, and the patient had been fol-
lowed for at least 5 years. The present study reports prima-
ry and secondary success rates of 87.5% (14/16 patients) 
and 100% (16/16), respectively, in OO treated with RFA 
and laser ablation including technical challenging locali-
sations. Besides OOs in typical locations, we successfully 
treated 2 intra-articular, 2 post prior unsuccessful ortho-
paedic resection, and 2 with thin cortical coverage. Lower 
primary success rates of 67% (16/24) [26], 76% (74/97) 
[19], 78% (18/23) [27], and 79% (30/38) [28], and compa-
rable success rates of 85–100% [17,29,30] were reported. 
Re-trial of recurred patients
In this study, there were 2 recurrent patients (2/16). In 
those patients (Patient #8 and Patient #10) recurrence 
appeared within 4 months of follow-up. The second RF 
treatment (Patient #8) and laser ablation (Patient #10) 
were clinically successful, and no patient had further com-
plaints. The mean period between first and second ablation 
was 9 months (Patient #8) and 10 months (Patient #10). 
We observed that in Patient #10 the nidus diminished af-
ter first ablation from 1290 mm3 to 476 mm3. The nidus 
in Patient #8 diminished insignificantly from 176 mm3 to 
170 mm3. No patient had residual pain after a repeat abla-
tion, and no patient needed surgical excision of the lesions.
A recent study showed only a non-diaphyseal loca-
tion of the OO as an independent risk factor and at least 
a trend towards a higher recurrence rate for OO larger 
than 10 mm in size [31]. Another study provided evidence 
of the size of the OO as the only independent risk factor 
for an incomplete ablation, with a significantly higher re-
currence rate for OOs larger than 10 mm. Location, sex, 
calcification, and coagulation time were not identified as 
risk factors [32]. The literature reports 5-25% recurrence 
with different treatment modalities [17,33]. Rosenthal re-
ported recurrence in 9% of cases with open procedures, 
whereas this rate was 12% with RFA [34]. Hoffmann con-
ducted a study on CT-guided RFA of OO and reported an 
8% recurrence rate [25]. In his study on interstitial OO 
laser ablation, Gangi had a 5.3% early and late recurrence 
rate [16].
Referrals after failed orthopaedic treatment 
Initial percutaneous ablation was performed in all cases, 
except for 2 patients (12.5%, 2/16) with persistent symp-
toms after they underwent unsuccessful open surgical re-
section in other hospitals (Figure 5). Both had had open 
resection of the lesion located in the tibia with no nidus in 
resected en block. We performed one session of ablation 
on them and gained good primary results at the follow-up. 
Long-term outcome
It was necessary to analyse long-term follow-ups of RFA 
and ILA to claim success, because it is possible for recur-
rence to occur in a 10-year period [20-23]. At the follow-
up between 5 and 10.2 years, 100% of the patients were 
classified as good. During the long-term follow-up period, 
no patients showed late recurrence. The average period of 
follow-up in our study was 7.5 years, which to the best of 
Figure 5. Patient with persistent symptoms after undergoing unsuccessful open surgical resection – biopsy: no nidus in resected en block bone (arrowhead). 
The nidus is still visible in the tibia (arrows) 
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our knowledge is the longest mean follow-up from pub-
lished studies. Daniilidis et al. described long-term follow-
up after RFA in 29 cases of OO with a mean follow-up of 
5.6 years (range 1.0-11.0 years) [35]. Long-term follow-
up was obtained by Abboud et al. for 24 patients – mean 
time to follow-up was 5 years (range 1.0-12.6 years) [36]. 
Rimondi et al. performed the largest study of RFA for OO 
to date, a retrospective review encompassing 557 patients 
with a mean follow-up period of 3.5 years [37]. 
Complications
In 1 patient, there was soft tissue oedema after the proce-
dure accompanied by nonspecific pain not related to OO, 
and there was no radiologic reflection of this clinical sign. 
The patient’s symptoms were relieved completely after 
2 months of a short course of high-dose prednisone in 
addition to physical therapy. Furthermore, no instances 
of skin burn next to the electrode entry and no neuro-
vascular compromise developed. Also, in our study, there 
were no complications; no treatment-related deaths, an-
aesthesia-related complications, fractures of weight-bear-
ing bones, or other late complications occurred. Previous 
studies reported complications such as skin burn, skin 
and fat necrosis, soft tissue infection, vasomotor instabil-
ity, tendinitis, and haematoma [17,20,33].
Analysis and management of osteoid osteoma
CT imaging allowed clear identification of the location 
and size of the lesions. In our study 83% of OO (14/16) 
were located in lower extremities, which determined spi-
nal anaesthesia. Conversely, two lesions at the upper limb 
determined regional nerve block. The tumour has a pro-
pensity for the major weight-bearing bones, especially 
the femur. Similarly to cases reported in the literature [8], 
the most common localisation in our study was the femur 
(50%). Two tumours were intra-articular – located within 
the capsule of the hip joints – and had associated joint ef-
fusions. In all cases, CT proved that lytic nidus with sur-
rounding reactive sclerosis and adjacent cortical thicken-
ing in the location correlating with the site of the patient’s 
pain. The median nidus volume of these cases was 
217 mm3. The largest observed nidus was 1290 mm3 in 
volume, and the smallest was only 6 mm3. According to 
other studies the median nidus volume of their cases was 
330 mm3 (range 120-2000 mm3) [38]. Central nidus cal-
cifications were observed in 14/16 cases, with the largest 
being 7 mm in length (mean 2.3 mm). The osteoid within 
the nidus undergoes various degrees of calcification and 
is associated with the production of irregular trabeculae 
of woven bone. Previous studies evaluating the treatment 
success of RFA found that the complete calcification of 
the nidus upon follow-up CT studies was associated with 
successful treatment [19]. The thickest perinidal reactive 
sclerosis and cortical thickness at the entry point was 
12 mm and was observed in the trochanter major of the 
femur. The thinnest sclerotic changes were 1 mm and 
were observed intraarticularly in the neck of the femur. 
All tumours in the present study were accessed with 
a single drill hole, except 1 tumour that was greater than 
10 mm in at least one dimension. In this case, 2 osseous 
channels were drilled for this lesion. These results may 
suggest that RFA and ILA are efficacious with a single os-
seous channel procedure applied to the OO smaller than 
10 mm, and efficacious if the probe is correctly centred 
by 2 or more bone drills in the nidus larger than 10 mm. 
The greatest distance from entry point at skin to the ni-
dus was 88 mm, which was observed around the hip. This 
can cause problems because the risk of misplacement is 
higher and sometimes the gantry is too small. The short-
est length of needle tract from entry point to the nidus 
was 11 mm, which was observed in the tibia. Problems 
with superficially located lesions require focus on proper 
needle fixation/stabilisation, and sometime extra distanc-
ing pad is required. Depending on OO localisation, the 
shortest distance through the bone was selected for ac-
cess. When such an approach was considered unsafe due 
to neurovascular structure proximity, joint capsule, or 
the approach being technically difficult, the lesion was 
reached by drilling from the opposite side of the bone 
(Figure 6).
Figure 6. Radiofrequency thermoablation of an osteoid osteoma located in the tibia. Due to the proximity of the neurovascular bundle, a transtibial approach 
was used to avoid any harm to critical structures 
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In some cases, it is difficult to visualise the nidus both 
in imaging studies and intraoperatively [14]. Computed 
tomography (CT) most effectively and precisely deter-
mines the nidus location and has become the method of 
choice when X-ray findings are ambiguous, almost com-
pletely supplanting the classic planar images [39,40].
Histological findings
Biopsies for histological confirmation are not routinely 
performed. The absence of histological confirmation of 
the diagnosis was not an exclusion criterion. Despite this, 
some biopsies were performed, and OO diagnosis was 
confirmed. Several authors conclude that clinical and ra-
diological examinations are enough to make a diagnosis, 
thus deeming pathological essay not mandatory [33]. This 
will also reduce patient costs. Despite this, a histopatho-
logical examination is still recommended for lesions at 
atypical sites [17]. At surgical resection or radiofrequency 
ablation, OO confirmation is obtained in 57-79% of cases 
when biopsy is performed [17,40,41]. For the remaining 
patients, no histological diagnosis was determined, due to 
insufficient material or inadequate specimens.
Advantages of percutaneous ablation 
Currently, the treatment options are varied, and percu-
taneous treatment is increasingly used. Radiofrequency 
ablation is widely validated as an efficient method with-
out serious adverse events and with a low rate of recur-
rence. Laser ablation is used for its ability to focus energy 
precisely on the ablation area. Rapid post-procedural re-
covery takes place after its use, and few substantial com-
plications are noted. The tip of the optical fibre acts as 
a point heat source. The size of the induced zone of abla-
tion depends on the laser wavelength, the thermal and 
optical properties of the tissue, total duration of energy 
application, the power used, fibre diameter, fibre tip, and 
the number of fibres used sequentially or simultaneously 
for ablation. Recurrences can be treated easily and effec-
tively with follow-up ILA. 
Disadvantages of ablation 
The standard of treatment currently consists of a mini-
invasive imaging-guided procedure (CT-guided ther-
moablation), although a percutaneous approach still 
has some drawbacks. Despite the high success rate of 
CT-guided thermoablation, there may be minor or ma-
jor complications from the procedure (e.g. a broken drill, 
infection, cellulitis, or sympathetic dystrophy). Needle po-
sitioning during CT-guided radiofrequency ablation may 
be challenging, and larger lesions may require multiple 
treatments or consecutive ablations in the same session, 
increasing the procedure time. The disadvantages of CT 
scans concern problems with radiological suite sterility, 
radiation, accuracy, and increased intra and postoperative 
complications [16]. Computed tomography is a good way 
of visualising the nidus and its surrounding soft tissue. 
However, it has some limitations in needle guidance. Real-
time guidance is not possible; therefore, CT-fluoroscopy 
is used. Some patients must be excluded from the per-
cutaneous ablation because of the inability to undergo 
a CT-guided procedure due to obesity, making them un-
able to fit in the gantry. Lack of space in a gantry is some-
time exaggerated by long RF needles. 
Limitations of radiofrequency thermoablation and 
interstitial laser ablation techniques 
Often RF ablation reaches “roll-off ” (i.e. a significant 
increase of impedance resulting in the loss of AC flow), 
indicating complete local coagulation necrosis/charring. 
In such cases, a manual repositioning of the electrode tip 
and restarting of the RFA must be done until deposition 
of the desired energy. A “dry tip” would also cause an early 
“roll-off”, and hence it is essential to wet the probe tip with 
a saline-soaked gauze and test conductivity before appli-
cation. Skin burn is known to be a complication of percu-
taneous RFA procedures [42]. Electricity, leaving a mono-
polar radiofrequency electrode, travels to a grounding pad 
placed on the patient’s skin, thus completing the circuit. 
The same amount of energy is deposited at the tip of the 
electrode and the skin pad, but a larger surface skin pad 
area dissipates the heat load. However, incorrect skin pad 
placement or other technical aberrations can result in 
skin burns [42]. This risk is negated with bipolar systems 
in which the neutral electrode is located in the ablation 
probe rather than a skin pad. 
The laser fibre is not radiopaque and additional ma-
noeuvres must be adapted to insert the fibre precisely. 
Despite this, the tip of the bare fibre cannot be monitored 
within the tumour in real-time. On the other hand, ILA 
instruments are more compatible with MR imaging than 
radiofrequency ablation when MR guidance is consid-
ered. A 400-μm optical fibre can be introduced through 
an 18-gauge spinal needle, although a simultaneous bi-
opsy cannot be performed in necessary cases.
Comparison of percutaneous ablation with other 
treatment methods
Magnetic resonance-guided focused ultrasound ablation
Magnetic resonance-guided focused ultrasound (MRgFUS) 
was described as an alternative form of therapy for symp-
tomatic OO [43]. MRgFUS is a novel imaging-guided ab-
lative technique that allows the performance of noninva-
sive and radiation-free ablation [44]. MRgFUS uses high 
acoustic energy for targeted tissue ablation under MR 
guidance with real-time thermal monitoring. Contrary 
to focused ultrasound therapy, MRI has the advantage 
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of lesion localisation and temperature monitoring. Le-
sions can be located by intrinsic high tissue MRI contrast. 
Temperature monitoring, on the other hand, is achieved 
with the use of specific MRI sequences performed in real 
time during ablation. MRgFUS is an attractive technique 
that carries substantial innovation to OO treatment. 
The success rate demonstrated by early studies was com-
parable with the results of clinical trials studying CT-
guided radiofrequency ablation (85% to 98%) [43,44]. In 
addition, this technique is noninvasive and requires no 
incision, eliminating the risk of infection. What is more, 
it also helps avoid exposing patients to ionising radiation, 
relevant when considering the young age distribution of 
those with OO. Claustrophobia, obesity, large sclerotic 
reaction around the OO, and lesion location close to neu-
rovascular bundles are considered a general limitation of 
the MRgFUS technique [43,44].
Operative excision 
Some intramedullary and subperiosteal lesions are dif-
ficult to localise intraoperatively because they may not 
demonstrate significant sclerosis. Furthermore, the cor-
tex overlying the site may appear normal during the 
procedure. Despite a lesion’s small size, the operative 
procedure for its removal can be extensive. Extended 
curettage and the en bloc resection of the whole lesion 
are surgical methods of OO treatment. It is possible that 
a tumour may recur if it is not completely removed dur-
ing the operation (Figure 5). The tumour has a propensi-
ty for major weight-bearing bones, especially the femur. 
There is a risk of fracture at such sites if a substantial 
amount of cortical bone is removed. Therefore, inter-
nal fixation and bone grafting may be necessary [34]. 
The operative length in open surgery is typically longer 
because exposure and wound closure take time. The need 
for increased soft tissue dissection and osseous manipula-
tion in open surgery causes more postoperative pain and 
lengthens hospital stay [34,45]. The possibility of histo-
pathological diagnosis is the main advantage of an open 
procedure.
Conservative treatment
The painful feature of OO explains the medical com-
munity’s specific consideration. OO is a painful benign 
bone tumour rarely treated, whereby non-steroidal anti-
inflammatory drugs (NSAIDs) are prescribed to bring 
relief. Therefore, to treat OO, long-term administration 
of NSAIDs can often be as effective as excision, without 
the morbidity that is associated with the operation, es-
pecially in patients in whom operative treatment would 
be complex or could lead to disability [46]. The patient 
must be under continuous observation and be clearly in-
formed about possible side effects. Blood count and liver 
and kidney functions must be monitored over a patient’s 
treatment period. Side effects from the continuous use of 
medication are mainly related to gastrointestinal prob-
lems. Skin irritations or central nervous system symptoms 
are extremely rare [10].
Study advantages
(1) The advantage of this study is a very long follow-up 
from 5 to 10 years post percutaneous thermoablation. To 
the best of our knowledge, it is the longest mean follow-up 
after OO ablation in the literature. (2) A relatively large 
sample of patients were treated with bipolar RFA, thus 
our data give an additional overview of this technique. 
The majority of the studies to date have used the mono-
polar system to evaluate the role of RFA in OO. Bipolar 
RFA of OO has been used in some small series, and only 
a few publications with a small sample of patients treated 
with CelonProSurge have been published: (n = 12) [47], 
(n = 1) [25]. (3) In our study we proposed automated nidal 
volume calculations by software-aided CT measurements, 
and we found this new application to be an easy tool to use 
for pre-procedural planning and follow-up. 
Limitations
The study has 2 limitations. Firstly, there was no routine 
histological confirmation. The diagnosis of OO was made 
by considering typical clinical symptoms and radiological 
findings, similarly to other authors [16,33]. Secondly is 
the small patients sample size, although the group size was 
on a par with other studies in the literature (n = 11) [48], 
(n = 18) [38], (n = 23) [27], (n = 23) [49].
Conclusions
The percutaneous tumour ablation is a very attractive al-
ternative to surgical resection and conservative treatment. 
The method relies on percutaneous needle application and 
thermal destruction of the nidus guided by CT. The long-
term results confirm the safety and efficacy of percutane-
ous radiofrequency ablation in patients with OO, upon 
a proper evaluation and successful primary and second-
ary treatment. RFA and ILA lead to better patient man-
agement by offering reduced invasiveness. Only 1 minor 
complication took place, and it is believed that CT guid-
ance is preferable to ensure that energy delivery by probe 
is within a safe margin from the neurovascular structure 
or the skin.
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